Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02579382
Other study ID # GS-US-283-1062
Secondary ID 2015-002017-30
Status Completed
Phase Phase 2
First received
Last updated
Start date November 10, 2015
Est. completion date May 3, 2019

Study information

Verified date May 2020
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.


Recruitment information / eligibility

Status Completed
Enrollment 192
Est. completion date May 3, 2019
Est. primary completion date January 16, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Key Inclusion Criteria:

- Adult males or females between the ages of 18-65

- Chronic hepatitis B virus (HBV) infection

- HBV deoxyribonucleic acid (DNA ) = 2000 IU/mL at screening

Key Exclusion Criteria:

- Extensive bridging fibrosis or cirrhosis

- Received oral antiviral treatment for HBV or prolonged therapy with immune-modulators or biologics within 3 months of screening

- Co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV) or hepatitis D virus (HDV)

- Chronic liver disease other than HBV

- Lactating or pregnant females or those that wish to become pregnant during the course of the study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Drug:
TDF
300 mg tablets administered orally once daily
Vesatolimod
Tablets administered orally once a week (every 7 days) for 12 doses
Placebo
Placebo administered orally once a week (every 7 days) for 12 doses

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  Canada,  Hong Kong,  Italy,  Korea, Republic of,  New Zealand,  Taiwan,  United Kingdom, 

References & Publications (4)

Agarwal K, Ahn SH, Elkhashab M, Kim K, Lau AH, Gaggar A, et al. Safety and efficacy ofvesatolimod (GS-9620) in patients with chronic hepatitis B (CHB) who are not currently on antiviral treatment. Poster 930. AASLD 2017. Hepatology; 66:497A 498A, 2017.

Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on an — View Citation

Lau A, Joshi A, Nguyen AH, Gaggar A, Patterson SD, Woo J. Peripheral blood immune cell profiling in virally suppressed chronic hepatitis B (CHB) patients and CHB patients not on an oral antiviral therapy. HBV International Meeting 2017.

Younossi ZM, Stepanova M, Janssen H, Agarwal K, Nguyen MH, Gane EJ, et al. The impact of treatment of chronic hepatitis B (CHB) on patient reported outcomes (PROs). Poster 1924. AASLD 2017. Hepatology; 66:1020A, 2017.

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change (Measured in log10 IU/mL) in Hepatitis B Surface Antigen (HBsAg) From Baseline at Week 24 The change from baseline to Week 24 in HBsAg (log10 IU/mL) was analyzed using a mixed model for repeated measures (MMRM). The model included treatment, baseline HBsAg (log10 IU/mL), baseline Hepatitis B Envelope Antigen (HBeAg) status (positive or negative), baseline alanine aminotransferase (ALT) level relative to upper limit of normal (ULN) (> 19 vs = 19 IU/L for females; > 30 vs = 30 IU/L for males), visit and treatment-by-visit interaction as fixed effects, and visit as a repeated measure. Baseline; Week 24
Secondary Percentage of Participants With HBeAg Loss and Seroconversion at Week 24 HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at any postbaseline visit. HBeAg seroconversion was defined as qualitative Hepatitis B Envelope Antibody (HBeAb) result changing from negative at baseline to positive at any postbaseline visit. The Missing (M) = Failure (F) approach was used for this analysis. Week 24
Secondary Percentage of Participants With HBeAg Loss and Seroconversion at Week 48 HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at any postbaseline visit. HBeAg seroconversion was defined as qualitative HBeAb result changing from negative at baseline to positive at any postbaseline visit. The Missing (M) = Failure (F) approach was used for this analysis. Week 48
Secondary Percentage of Participants With HBsAg Loss and Seroconversion at Week 24 HBsAg loss was defined as qualitative HBsAg result changing from positive at baseline to negative at any postbaseline visit. HBsAg seroconversion was defined as qualitative Hepatitis B Surface Antibody (HBsAb) result changing from negative at baseline to positive at any postbaseline visit. The Missing (M) = Failure (F) approach was used for this analysis. Week 24
Secondary Percentage of Participants With HBsAg Loss and Seroconversion at Week 48 HBsAg loss was defined as qualitative HBsAg result changing from positive at baseline to negative at any postbaseline visit. HBsAg seroconversion was defined as qualitative HBsAb result changing from negative at baseline to positive at any postbaseline visit. The Missing (M) = Failure (F) approach was used for this analysis. Week 48
Secondary Mean Change (Measured in log10 IU/mL) in HBsAg From Baseline at Week 12 Baseline; Week 12
Secondary Mean Change (Measured in log10 IU/mL) in HBsAg From Baseline at Week 48 Baseline; Week 48
Secondary Percentage of Participants With a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers From Baseline at Week 12 HBsAg = 0.5 log10 IU/mL decline was defined as a decline from baseline in log10 IU/mL serum HBsAg = 0.5 at the Week 12 post-baseline visit. Missing values were considered failures. Baseline to Week 12
Secondary Percentage of Participants With a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers From Baseline at Week 24 HBsAg = 0.5 log10 IU/mL decline was defined as a decline from baseline in log10 IU/mL serum HBsAg = 0.5 at the Week 24 post-baseline visit. Baseline to Week 24
Secondary Percentage of Participants With a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers From Baseline at Week 48 HBsAg = 0.5 log10 IU/mL decline was defined as a decline from baseline in log10 IU/mL serum HBsAg = 0.5 at the Week 12 post-baseline visit. Missing values were considered failures. Baseline to Week 48
Secondary Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) < Lower Limit of Quantitation (LLOQ) at Week 24 LLOQ for HBV DNA was defined as 20 IU/mL. The participants with missing information were excluded from the analysis. Week 24
Secondary Percentage of Participants With HBV DNA < LLOQ at Week 48 LLOQ for HBV DNA was defined as 20 IU/mL. The participants with missing information were excluded from the analysis. Week 48
Secondary Percentage of Participants Experiencing Virologic Breakthrough Virologic breakthrough was defined as confirmed HBV DNA = 69 IU/mL after having had HBV DNA < 69 IU/mL or confirmed 1.0 log10 IU/mL or greater increase in HBV DNA from nadir. Confirmation requires 2 consecutive occurrences of elevation in HBV DNA to > 69 IU/mL after having had HBV DNA < 69 IU/mL or 1.0 log10 IU/mL or greater increases in HBV DNA from nadir. Weeks 24 and 48
Secondary Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase/Reverse Transcriptase (Pol/RT) Sequence analysis of the HBV pol/RT was attempted for any participant who had HBV DNA = 69 IU/mL at Week 48 or early discontinuation. Results of the alignment of Week 48 and baseline sequence were reported as a change from baseline sequence. Baseline; Week 48
Secondary Pharmacokinetic (PK) Parameter: AUClast of Vesatolimod AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: AUCinf of Vesatolimod AUCinf is defined as the concentration of drug extrapolated to infinite time. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: %AUCexp of Vesatolimod %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: Cmax of Vesatolimod Cmax is defined as the maximum concentration of drug. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: Clast of Vesatolimod Clast is defined as the last observable concentration of drug. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: Tmax of Vesatolimod Tmax is defined as the time (observed time point) of Cmax Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: Tlast of Vesatolimod Tlast is defined as the time (observed time point) of Clast. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: T1/2 of Vesatolimod T1/2 is defined as the estimate of the terminal elimination half-life of the drug. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
Secondary PK Parameter: CL/F of Vesatolimod CL/F is defined as the apparent oral clearance following administration of the drug. Week 11: Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A